BR112019007872A2 - inibidores duplos de vista e das vias pd-1 - Google Patents
inibidores duplos de vista e das vias pd-1Info
- Publication number
- BR112019007872A2 BR112019007872A2 BR112019007872A BR112019007872A BR112019007872A2 BR 112019007872 A2 BR112019007872 A2 BR 112019007872A2 BR 112019007872 A BR112019007872 A BR 112019007872A BR 112019007872 A BR112019007872 A BR 112019007872A BR 112019007872 A2 BR112019007872 A2 BR 112019007872A2
- Authority
- BR
- Brazil
- Prior art keywords
- inhibitors
- sight
- relates
- double
- double sight
- Prior art date
Links
- 239000012270 PD-1 inhibitor Substances 0.000 title 1
- 239000012668 PD-1-inhibitor Substances 0.000 title 1
- 229940121655 pd-1 inhibitor Drugs 0.000 title 1
- 239000003112 inhibitor Substances 0.000 abstract 2
- -1 3-substituted 1,2,4-oxadiazole compounds Chemical class 0.000 abstract 1
- 108060003951 Immunoglobulin Proteins 0.000 abstract 1
- 230000004913 activation Effects 0.000 abstract 1
- 238000003782 apoptosis assay Methods 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 102000018358 immunoglobulin Human genes 0.000 abstract 1
- 230000001506 immunosuppresive effect Effects 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 239000003446 ligand Substances 0.000 abstract 1
- 230000005522 programmed cell death Effects 0.000 abstract 1
- 230000019491 signal transduction Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4245—Oxadiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
- C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
- C07D271/06—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Abstract
a presente invenção refere-se a compostos de 1,2,4-oxadiazol 3-substituídos e seus derivados, que são úteis como supressores de imunoglobulina de domínio v de inibidores de ativação de células t (vista) ou como inibidores duplos de vista e a via de sinalização de morte celular programada 1 (pd-1). a divulgação também se refere ao tratamento de distúrbios inibindo um sinal imunossupressor induzido por vista e seus ligantes, pd-1, pd-l1 e/ou pd-l2.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IN201641035996 | 2016-10-20 | ||
PCT/IB2017/056463 WO2018073754A1 (en) | 2016-10-20 | 2017-10-18 | Dual inhibitors of vista and pd-1 pathways |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112019007872A2 true BR112019007872A2 (pt) | 2019-07-02 |
Family
ID=62019280
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112019007872A BR112019007872A2 (pt) | 2016-10-20 | 2017-10-18 | inibidores duplos de vista e das vias pd-1 |
Country Status (14)
Country | Link |
---|---|
US (1) | US20200061030A1 (pt) |
EP (1) | EP3529235A4 (pt) |
JP (2) | JP7189870B2 (pt) |
KR (1) | KR20190067235A (pt) |
CN (1) | CN110139856A (pt) |
AU (1) | AU2017345500B2 (pt) |
BR (1) | BR112019007872A2 (pt) |
CA (1) | CA3040033A1 (pt) |
EA (1) | EA201990997A1 (pt) |
IL (2) | IL266042A (pt) |
MX (1) | MX2019004561A (pt) |
PH (1) | PH12019500780A1 (pt) |
SG (2) | SG10202010584XA (pt) |
WO (1) | WO2018073754A1 (pt) |
Families Citing this family (41)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PL3363790T3 (pl) | 2013-09-06 | 2020-07-27 | Aurigene Discovery Technologies Limited | Pochodne 1,2,4-oksadiazolu jako immunomodulatory |
CA3220902A1 (en) | 2015-03-10 | 2016-09-15 | Aurigene Discovery Technologies Limited | 1,2,4-oxadiazole and thiadiazole compounds as immunomodulators |
IL265921B1 (en) | 2016-10-14 | 2024-01-01 | Prec Biosciences Inc | Transgenic meganonucleases specific for recognition sequences in the hepatitis B virus genome |
WO2019061324A1 (en) | 2017-09-29 | 2019-04-04 | Curis Inc. | CRYSTALLINE FORMS OF IMMUNOMODULATORS |
JP2020536872A (ja) | 2017-10-11 | 2020-12-17 | オーリジーン ディスカバリー テクノロジーズ リミテッドAurigene Discovery Technologies Limited | 3−置換1,2,4−オキサジアゾールの結晶形態 |
US11497734B2 (en) | 2017-11-03 | 2022-11-15 | Aurigene Discovery Technologies Limited | Dual inhibitors of TIM-3 and PD-1 pathways |
CA3081675A1 (en) | 2017-11-06 | 2019-05-09 | Aurigene Discovery Technologies Limited | Conjoint therapies for immunomodulation |
US10966999B2 (en) | 2017-12-20 | 2021-04-06 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 3′3′ cyclic dinucleotides with phosphonate bond activating the sting adaptor protein |
JP7098748B2 (ja) | 2017-12-20 | 2022-07-11 | インスティチュート オブ オーガニック ケミストリー アンド バイオケミストリー エーエスシーアール,ヴイ.ヴイ.アイ. | Stingアダプタータンパク質を活性化するホスホン酸結合を有する2’3’環状ジヌクレオチド |
JP7050165B2 (ja) | 2018-02-26 | 2022-04-07 | ギリアード サイエンシーズ, インコーポレイテッド | Hbv複製阻害剤としての置換ピロリジン化合物 |
US20210379024A1 (en) * | 2018-03-14 | 2021-12-09 | Aurigene Discovery Technologies Limited | Method of modulating tigit and pd-1 signalling pathways using 1,2,4-oxadiazole compounds |
WO2019195181A1 (en) | 2018-04-05 | 2019-10-10 | Gilead Sciences, Inc. | Antibodies and fragments thereof that bind hepatitis b virus protein x |
CN111954675A (zh) | 2018-04-06 | 2020-11-17 | 捷克共和国有机化学与生物化学研究所 | 3’3’-环二核苷酸 |
TWI818007B (zh) | 2018-04-06 | 2023-10-11 | 捷克科學院有機化學與生物化學研究所 | 2'3'-環二核苷酸 |
TW202005654A (zh) | 2018-04-06 | 2020-02-01 | 捷克科學院有機化學與生物化學研究所 | 2,2,─環二核苷酸 |
US11142750B2 (en) | 2018-04-12 | 2021-10-12 | Precision Biosciences, Inc. | Optimized engineered meganucleases having specificity for a recognition sequence in the Hepatitis B virus genome |
US20190359645A1 (en) | 2018-05-03 | 2019-11-28 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 2'3'-cyclic dinucleotides comprising carbocyclic nucleotide |
WO2020028097A1 (en) | 2018-08-01 | 2020-02-06 | Gilead Sciences, Inc. | Solid forms of (r)-11-(methoxymethyl)-12-(3-methoxypropoxy)-3,3-dimethyl-8-0x0-2,3,8,13b-tetrahydro-1h-pyrido[2,1-a]pyrrolo[1,2-c] phthalazine-7-c arboxylic acid |
CN113227089A (zh) | 2018-10-31 | 2021-08-06 | 吉利德科学公司 | 作为hpk1抑制剂的取代的6-氮杂苯并咪唑化合物 |
TWI721624B (zh) | 2018-10-31 | 2021-03-11 | 美商基利科學股份有限公司 | 經取代之6-氮雜苯并咪唑化合物 |
MX2021005240A (es) * | 2018-11-08 | 2021-06-18 | Aurigene Discovery Tech Ltd | Combinacion de inhibidores de peque?as moleculas cd-47 con otros agentes anticancer. |
EP3935065A1 (en) | 2019-03-07 | 2022-01-12 | Institute of Organic Chemistry and Biochemistry ASCR, V.V.I. | 3'3'-cyclic dinucleotide analogue comprising a cyclopentanyl modified nucleotide as sting modulator |
CN113543851A (zh) | 2019-03-07 | 2021-10-22 | 捷克共和国有机化学与生物化学研究所 | 2’3’-环二核苷酸及其前药 |
KR20210137518A (ko) | 2019-03-07 | 2021-11-17 | 인스티튜트 오브 오가닉 케미스트리 앤드 바이오케미스트리 에이에스 씨알 브이.브이.아이. | 3'3'-사이클릭 다이뉴클레오티드 및 이의 프로드럭 |
TWI751517B (zh) | 2019-04-17 | 2022-01-01 | 美商基利科學股份有限公司 | 類鐸受體調節劑之固體形式 |
TW202210480A (zh) | 2019-04-17 | 2022-03-16 | 美商基利科學股份有限公司 | 類鐸受體調節劑之固體形式 |
WO2020237025A1 (en) | 2019-05-23 | 2020-11-26 | Gilead Sciences, Inc. | Substituted exo-methylene-oxindoles which are hpk1/map4k1 inhibitors |
EP4017476A1 (en) | 2019-08-19 | 2022-06-29 | Gilead Sciences, Inc. | Pharmaceutical formulations of tenofovir alafenamide |
JP7398556B2 (ja) | 2019-09-30 | 2023-12-14 | ギリアード サイエンシーズ, インコーポレイテッド | Hbvワクチン及びhbvを治療する方法 |
WO2021113765A1 (en) | 2019-12-06 | 2021-06-10 | Precision Biosciences, Inc. | Optimized engineered meganucleases having specificity for a recognition sequence in the hepatitis b virus genome |
TW202200161A (zh) | 2020-03-20 | 2022-01-01 | 美商基利科學股份有限公司 | 4’-c-經取代-2-鹵基-2’-去氧腺苷核苷之前藥及其製造與使用方法 |
CN113679724B (zh) * | 2020-05-18 | 2023-04-07 | 中国科学院微生物研究所 | 一种流感病毒小分子抑制剂 |
CA3194742A1 (en) | 2020-09-10 | 2022-03-17 | Nammi Therapeutics, Inc. | Formulated and/or co-formulated liposome compositions containing pd-1 antagonist prodrugs useful in the treatment of cancer and methods thereof |
TW202310852A (zh) | 2021-05-13 | 2023-03-16 | 美商基利科學股份有限公司 | TLR8調節化合物及抗HBV siRNA療法之組合 |
KR20240019283A (ko) | 2021-06-11 | 2024-02-14 | 길리애드 사이언시즈, 인코포레이티드 | Mcl-1 저해제와 항암제의 병용 |
TW202317200A (zh) | 2021-06-11 | 2023-05-01 | 美商基利科學股份有限公司 | Mcl-1抑制劑與抗體藥物接合物之組合 |
CA3222439A1 (en) | 2021-06-23 | 2022-12-29 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
AU2022299051A1 (en) | 2021-06-23 | 2023-12-07 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
CN117396478A (zh) | 2021-06-23 | 2024-01-12 | 吉利德科学公司 | 二酰基甘油激酶调节化合物 |
WO2022271677A1 (en) | 2021-06-23 | 2022-12-29 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
WO2023219948A1 (en) * | 2022-05-08 | 2023-11-16 | The Regents Of The University Of Colorado, A Body Corporate | Therapeutic biomaterial that attenuates the foreign body response |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PL3363790T3 (pl) * | 2013-09-06 | 2020-07-27 | Aurigene Discovery Technologies Limited | Pochodne 1,2,4-oksadiazolu jako immunomodulatory |
CN107427476A (zh) * | 2015-03-10 | 2017-12-01 | 奥瑞基尼探索技术有限公司 | 作为免疫调节剂的3‑取代的‑1,2,4‑噁二唑和噻二唑化合物 |
CA3220902A1 (en) | 2015-03-10 | 2016-09-15 | Aurigene Discovery Technologies Limited | 1,2,4-oxadiazole and thiadiazole compounds as immunomodulators |
WO2018047143A1 (en) * | 2016-09-12 | 2018-03-15 | Aurigene Discovery Technologies Limited | Vista signaling pathway inhibitory compounds useful as immunomodulators |
-
2017
- 2017-10-18 SG SG10202010584XA patent/SG10202010584XA/en unknown
- 2017-10-18 WO PCT/IB2017/056463 patent/WO2018073754A1/en unknown
- 2017-10-18 MX MX2019004561A patent/MX2019004561A/es unknown
- 2017-10-18 JP JP2019520894A patent/JP7189870B2/ja active Active
- 2017-10-18 BR BR112019007872A patent/BR112019007872A2/pt unknown
- 2017-10-18 SG SG11201903103VA patent/SG11201903103VA/en unknown
- 2017-10-18 CN CN201780078731.XA patent/CN110139856A/zh active Pending
- 2017-10-18 EP EP17862427.6A patent/EP3529235A4/en active Pending
- 2017-10-18 EA EA201990997A patent/EA201990997A1/ru unknown
- 2017-10-18 CA CA3040033A patent/CA3040033A1/en active Pending
- 2017-10-18 AU AU2017345500A patent/AU2017345500B2/en active Active
- 2017-10-18 KR KR1020197014205A patent/KR20190067235A/ko not_active Application Discontinuation
- 2017-10-18 US US16/343,681 patent/US20200061030A1/en active Pending
-
2019
- 2019-04-11 PH PH12019500780A patent/PH12019500780A1/en unknown
- 2019-04-15 IL IL266042A patent/IL266042A/en unknown
-
2021
- 2021-10-24 IL IL287518A patent/IL287518A/en unknown
-
2022
- 2022-09-16 JP JP2022148392A patent/JP2022191239A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
SG11201903103VA (en) | 2019-05-30 |
SG10202010584XA (en) | 2020-12-30 |
KR20190067235A (ko) | 2019-06-14 |
IL266042A (en) | 2019-06-30 |
AU2017345500A1 (en) | 2019-05-23 |
JP2019532083A (ja) | 2019-11-07 |
EP3529235A4 (en) | 2020-07-08 |
JP7189870B2 (ja) | 2022-12-14 |
WO2018073754A1 (en) | 2018-04-26 |
US20200061030A1 (en) | 2020-02-27 |
EP3529235A1 (en) | 2019-08-28 |
AU2017345500B2 (en) | 2022-03-10 |
CN110139856A (zh) | 2019-08-16 |
EA201990997A1 (ru) | 2019-08-30 |
CA3040033A1 (en) | 2018-04-26 |
IL287518A (en) | 2021-12-01 |
PH12019500780A1 (en) | 2019-08-05 |
MX2019004561A (es) | 2019-08-05 |
NZ753204A (en) | 2023-09-29 |
JP2022191239A (ja) | 2022-12-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112019007872A2 (pt) | inibidores duplos de vista e das vias pd-1 | |
BR112017019307A2 (pt) | compostos de 1,3,4-oxadiazol 3-substituído e tiadiazol como imunomoduladores | |
EA201791621A1 (ru) | 3-замещенные-1,2,4-оксадиазольные и тиадиазольные соединения в качестве иммуномодуляторов | |
EA201791629A1 (ru) | 1,3,4-оксадиазольные и тиадиазольные соединения в качестве иммуномодуляторов | |
BR112017019305A2 (pt) | compostos cíclicos terapêuticos como imunomoduladores | |
PH12020550511A1 (en) | Dual inhibitors of tim-3 and pd-1 pathways | |
CL2015002529A1 (es) | Compuestos de tetrahidropirrolotiazina | |
GT201600215A (es) | Compuestos de heteroarilo o arilo bicíclicos fusionados y su uso como inhibidores de irak4 | |
BR112018011053A2 (pt) | derivados de oxadiazol microbiocidas | |
MX2017011618A (es) | Compuestos de 1,2,4-oxadiazol y tiadiazol como inmunomoduladores. | |
PH12018502535B1 (en) | Substituted carbonucleoside derivatives useful as anticancer agents | |
CL2018000338A1 (es) | Derivados de heteroarilo como inhiidores de parp | |
BR112018012390A2 (pt) | derivados de oxadiazol microbiocidas | |
SG10201908839QA (en) | 2,4-dihydroxy-nicotinamides as apj agonists | |
BR112018012378A2 (pt) | derivados de oxadiazol microbiocidas | |
BR112018073619A2 (pt) | derivados de oxadiazol microbiocidas | |
CL2017001511A1 (es) | Derivados de piperidina como inhibidores de hdac1/2. | |
CL2019002019A1 (es) | Nuevo compuesto heterocíclico, su método de preparación y composición farmacéutica que lo comprende. | |
BR112018005936A2 (pt) | inibidores de isoindolinona da interação de mdm2-p53 que têm atividade anticâncer | |
BR112018012825A2 (pt) | derivados de oxadiazol microbiocidas | |
EA201990159A1 (ru) | Биарилметильные гетероциклы | |
BR112018068358A2 (pt) | derivados de oxadiazol microbiocidas | |
BR112018012338A2 (pt) | derivados de oxadiazol microbiocidas | |
EA201791058A1 (ru) | Морфолин- и 1,4-оксазепан-амиды в качестве агонистов соматостатинового рецептора подтипа 4 (sstr4) | |
MA39163A1 (fr) | Forme cristalline de (s)-(2-(6-chloro-7-methyl-1h-benzo[d]imidazol-2-yl)-2-methylpyrrolidin-1 -yl)(5-methoxy-2-(2h-1,2,3-triazol-2-yl)phenyl)methanone et utilisation de celle-ci en tant qu'antagonistes des recepteurs de l'orexine |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B15K | Others concerning applications: alteration of classification |
Free format text: A CLASSIFICACAO ANTERIOR ERA: C07D 271/06 Ipc: A61K 31/4245 (2006.01), A61K 31/422 (2006.01), C07 |
|
B06W | Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette] | ||
B350 | Update of information on the portal [chapter 15.35 patent gazette] | ||
B25D | Requested change of name of applicant approved |
Owner name: AURIGENE ONCOLOGY LIMITED (IN) |